News

News Subscription

Nov 02. 2022
Basilea announces sale of preclinical oncology program to Twentyeight-Seven Therapeutics
Read more
Download
Oct 24. 2022
ERADICATE phase 3 study results highlight the potential role of ceftobiprole in the treatment of Staphylococcus aureus bacteremia (SAB)
Read more
Download
Oct 13. 2022
Basilea announces late breaking presentation on the successfully completed ERADICATE phase 3 study with ceftobiprole in Staphylococcus aureus bacteremia (SAB) at IDWeek 2022
Read more
Download
Sep 21. 2022
Basilea announces closing of CHF 75 million senior secured loan agreement with Athyrium
Read more
Download
Sep 20. 2022 / Ad hoc announcement
Basilea announces acquisition of rights for oncology asset BAL0891 by SillaJen and updates financial guidance
Read more
Download
Sep 08. 2022
Basilea announces sale of preclinical oncology program to Nodus Oncology
Read more
Download
Sep 07. 2022 / Ad hoc announcement
Basilea announces CHF 75 million senior secured loan agreement with Athyrium for non-dilutive refinancing of convertible bonds due in December 2022
Read more
Download
Aug 16. 2022 / Ad hoc announcement
Basilea reports strong financial half-year results and progress in the implementation of new anti-infectives strategy
Read more
Download
Jul 12. 2022
Basilea announces Zevtera® (ceftobiprole) marketing authorization in Brazil
Read more
Download
Jun 28. 2022 / Ad hoc announcement
Basilea announces positive results of phase 3 ERADICATE study with ceftobiprole in Staphylococcus aureus bacteremia (SAB)
Read more
Download